The field of HER2-positive gastrointestinal malignancies witnessed a surge of data in 2020 regarding investigational agents, such as the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki, that could play a pivotal role in transforming treatment selection in the coming years.
January 11, 2021 — The FDA has granted an orphan drug designation to the novel intratumoral immunotherapy agent PVSRIPO for the treatment of patients with advanced melanoma, specifically those with stage IIIB-IV disease.
Joshua G. Cohen, MD, FACOG, FACS, discusses the efficacy of PARP inhibitors in ovarian cancer, remaining questions regarding repeat inhibition and treatment duration, and the potential for combinations.
Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the benefit achieved with standard-of-care radiation therapy plus androgen deprivation therapy with a luteinising hormone-releasing hormone analogue.
January 11, 2021 - Larotrectinib was found to induce a high response rate with long durability and improve survival in patients with TRK-positive sarcomas, according to results from an analysis of 3 clinical trials.
Although rates of hepatocellular carcinoma incidence started to plateau in 2013, many cases continue to be diagnosed at more advanced stages, especially in patients without liver disease.
Sarah Goldberg, MD, MPH, discusses a network meta-analysis of randomized trials of chemoimmunotherapy with in patients with advanced disease, data suggest that certain populations with high, and perhaps low, PD-L1 expression may not require combination therapy, which would minimize adverse event potential.
Martine J. Piccart discusses her journey into the breast cancer treatment space.
The development of additional molecularly targeted therapies and the search for enhanced immunotherapy regimens are expected to permeate the oncology landscape across a broad range of malignancies as 2021 unfolds.
January 8, 2021 — The combination of osimertinib plus bevacizumab failed to result in a statistically significant improvement in progression-free survival versus osimertinib alone in patients with advanced lung adenocarcinoma that harbored an EGFR T790M mutation.
Brexucabtagene autoleucel induced durable response in patients with relapsed/refractory mantle cell lymphoma, according to findings from the phase 2 ZUMA-2 trial, leading to an FDA approval for use in this patient population on July 24, 2020.
January 8, 2021 - The FDA has approved a supplemental new drug application to add overall survival and other secondary end point data from the phase 3 ARAMIS trial to the prescribing information for darolutamide for the treatment of patients with nonmetastatic prostate cancer.
January 8th, 2021 - The United Kingdom’s National Institute for Health and Care Excellence has issued guidelines recommending against nivolumab for use in patients with recurrent or metastatic head and neck squamous cell carcinoma who experienced disease progression during or after platinum-based chemotherapy.
January 8, 2021 — The FDA has granted a fast track designation to zenocutuzumab for the treatment of patients with metastatic solid tumors that harbor NRG1 gene fusions and have progressed on standard-of-care treatment.
Maha H.A. Hussain, MD, and Mary-Ellen Taplin, MD, sit down with OncLive® to travel the road that led them to specialize in genitourinary oncology, the challenges they experienced as a female in the field, and advice they would give to not only other rising female oncologists, but to their younger selves knowing what they know now.
Yujie Zhao, MD, PhD, highlights molecular testing and how it's a critical component of the treatment selection process in lung cancer, as a host of effective drugs have since been developed to target alterations such as ALK, ROS1, and RET.
January 7, 2021 - The reversible BET inhibitor CC-90010 was found to have preliminary antitumor activity in patients with heavily pretreated, advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma.
January 7th, 2021 - The addition of eganelisib to nivolumab was found to elicit encouraging responses and improve progression-free survival compared with single-agent nivolumab in patients with platinum-refractory, immunotherapy-naïve, advanced, metastatic urothelial cancer.
Brendon Stiles, MD, discusses his approach to treating patients with early-stage and metastatic lung cancer, the importance of molecular testing and screening, and remaining challenges in the space.
January 7, 2021 - Patients with pancreatic ductal adenocarcinoma who were treated with a 920 mg dose of SM-88 were less likely to experience a change in tumor texture and were found to have more favorable outcomes, according to results from a phase 2 dose-escalation trial.
January 7, 2020 - The FDA has approved the request submitted by Moleculin Biotech, Inc. for rare disease designations to be granted their drug candidate WP1066, an agent that appears to directly elicit tumor cell death and rouse the immune system to eliminate tumors.
VERU-111, a next-generation form of chemotherapy, has shown promising signs of efficacy as a treatment option for men with metastatic castration-resistant prostate cancer whose disease has progressed while receiving androgen receptor–targeting therapy.
Yanyan Lou, MD, PhD, highlighted the role of atezolizumab, durvalumab, pembrolizumab, and nivolumab and how they have demonstrated improved survival in combination with etoposide and platinum in untreated extensive-stage small cell lung cancer, cementing checkpoint inhibition plus chemotherapy as a frontline standard.
Germline predisposition variants associated with cancer susceptibility syndromes can underlie the genetic risk for rhabdomyosarcoma, indicating that germline testing should be performed in accordance with RMS subtypes and irrespective of age.
January 6, 2021 - The MOMENTUM trial will randomize patients to receive momelotinib or danazol to determine which regimen shows more efficacy against the MF hallmarks of anemia, constitutional symptoms, and splenomegaly.
January 6, 2021 — The oral small molecule inhibitor VS-6766, developed by Verastem Oncology, is now under investigation alone and in combination with the FAK inhibitor defactinib in a recently initiated, registration-directed, phase 2 trial in patients with recurrent low-grade serous ovarian cancer.
James Gerson, MD, discusses the introduction of CAR T-cell therapy to the mantle cell lymphoma armamentarium and how induction therapy followed by stem cell transplant has maintained a role.
January 6, 2020 - The FDA has deferred action on the biologics license application for the proposed bevacizumab biosimilar MYL-1402O.
A community can be defined by any number of characteristics. In Lonial’s case, he has built a community of physicians who’ve come together to treat patients with multiple myeloma.
January 6th, 2021 - The addition of vemurafenib to irinotecan and cetuximab led to a significant improvement in progression-free survival versus irinotecan and cetuximab alone in patients with BRAF V600E–mutated metastatic colorectal cancer.
